231 related articles for article (PubMed ID: 35701800)
1. Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.
Bartlett TE; Evans I; Jones A; Barrett JE; Haran S; Reisel D; Papaikonomou K; Jones L; Herzog C; Pashayan N; Simões BM; Clarke RB; Evans DG; Ghezelayagh TS; Ponandai-Srinivasan S; Boggavarapu NR; Lalitkumar PG; Howell SJ; Risques RA; Rådestad AF; Dubeau L; Gemzell-Danielsson K; Widschwendter M
Genome Med; 2022 Jun; 14(1):64. PubMed ID: 35701800
[TBL] [Abstract][Full Text] [Related]
2. Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.
Communal L; Vilasco M; Hugon-Rodin J; Courtin A; Mourra N; Lahlou N; Le Guillou M; Perrault de Jotemps M; Chauvet MP; Chaouat M; Pujol P; Feunteun J; Delaloge S; Forgez P; Gompel A
Oncotarget; 2016 Jul; 7(29):45317-45330. PubMed ID: 27246982
[TBL] [Abstract][Full Text] [Related]
3. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
[TBL] [Abstract][Full Text] [Related]
4. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
5. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M
Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.
Tung N; Wang Y; Collins LC; Kaplan J; Li H; Gelman R; Comander AH; Gallagher B; Fetten K; Krag K; Stoeckert KA; Legare RD; Sgroi D; Ryan PD; Garber JE; Schnitt SJ
Breast Cancer Res; 2010; 12(1):R12. PubMed ID: 20149218
[TBL] [Abstract][Full Text] [Related]
7. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
8. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.
Lee E; McKean-Cowdin R; Ma H; Spicer DV; Van Den Berg D; Bernstein L; Ursin G
J Clin Oncol; 2011 Nov; 29(33):4373-80. PubMed ID: 22010008
[TBL] [Abstract][Full Text] [Related]
10. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties.
Axlund SD; Yoo BH; Rosen RB; Schaack J; Kabos P; Labarbera DV; Sartorius CA
Horm Cancer; 2013 Feb; 4(1):36-49. PubMed ID: 23184698
[TBL] [Abstract][Full Text] [Related]
11. Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.
Mahfoudh W; Bettaieb I; Ghedira R; Snoussi K; Bouzid N; Klayech Z; Gabbouj S; Remadi Y; Hassen E; Bouaouina N; Zakhama A
J Transl Med; 2019 Apr; 17(1):123. PubMed ID: 30975216
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 mutation influences progesterone response in human benign mammary organoids.
Davaadelger B; Choi MR; Singhal H; Clare SE; Khan SA; Kim JJ
Breast Cancer Res; 2019 Nov; 21(1):124. PubMed ID: 31771627
[TBL] [Abstract][Full Text] [Related]
13. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist.
Poole AJ; Li Y; Kim Y; Lin SC; Lee WH; Lee EY
Science; 2006 Dec; 314(5804):1467-70. PubMed ID: 17138902
[TBL] [Abstract][Full Text] [Related]
14. Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA
Ponandai-Srinivasan S; Lalitkumar PG; Garcia L; Varghese SJ; Carlson JW; Gemzell-Danielsson K; Floter Radestad A
Acta Obstet Gynecol Scand; 2019 Feb; 98(2):250-261. PubMed ID: 30325501
[TBL] [Abstract][Full Text] [Related]
15. Chromosomal radiosensitivity of triple negative breast cancer patients.
Francies FZ; Herd O; Cairns A; Nietz S; Murdoch M; Slabbert J; Claes KBM; Vral A; Baeyens A
Int J Radiat Biol; 2019 Nov; 95(11):1507-1516. PubMed ID: 31348739
[No Abstract] [Full Text] [Related]
16. Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs.
Knutson TP; Truong TH; Ma S; Brady NJ; Sullivan ME; Raj G; Schwertfeger KL; Lange CA
J Hematol Oncol; 2017 Apr; 10(1):89. PubMed ID: 28412963
[TBL] [Abstract][Full Text] [Related]
17. Pathological characteristics of BRCA-associated breast cancers in Hispanics.
Lagos-Jaramillo VI; Press MF; Ricker CN; Dubeau L; Mai PL; Weitzel JN
Breast Cancer Res Treat; 2011 Nov; 130(1):281-9. PubMed ID: 21604016
[TBL] [Abstract][Full Text] [Related]
18. Selective progesterone receptor blockade prevents BRCA1-associated mouse mammary tumors through modulation of epithelial and stromal genes.
Lee O; Bosland MC; Wang M; Shidfar A; Hosseini O; Xuei X; Patel P; Schipma MJ; Helenowski I; Kim JJ; Clare SE; Khan SA
Cancer Lett; 2021 Nov; 520():255-266. PubMed ID: 34329741
[TBL] [Abstract][Full Text] [Related]
19. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.
Anders CK; Carey LA
Clin Breast Cancer; 2009 Jun; 9 Suppl 2(Suppl 2):S73-81. PubMed ID: 19596646
[TBL] [Abstract][Full Text] [Related]
20. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.
Paranjape T; Heneghan H; Lindner R; Keane FK; Hoffman A; Hollestelle A; Dorairaj J; Geyda K; Pelletier C; Nallur S; Martens JW; Hooning MJ; Kerin M; Zelterman D; Zhu Y; Tuck D; Harris L; Miller N; Slack F; Weidhaas J
Lancet Oncol; 2011 Apr; 12(4):377-86. PubMed ID: 21435948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
